Terje R. Pedersen - Concepedia

Author

Terje R. Pedersen

Also Known As

Alexander Parkhomenko, Borislava Mihaylova, G. Masotti, Helge Istad, John La Rosa, Pedersen, T. R., T R Pedersen, T. R Pedersen, T. R. Pedersen, T.R Pedersen

248

Publications

69.2K

Citations

H-Index

Concepts

All Affiliations

Oslo University Hospital University of Oslo Brigham and Women's Hospital Thrombolysis in Myocardial Infarction Study Group National Health and Medical Research Council

About

Terje R. Pedersen is an author at Oslo University Hospital specializing in medicine, cardiovascular disease, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	56	14.6K
2	Public Health	28	38	10.4K
3	Health Sciences	6	6	258
4	Arts	1	1	41
5	Social Sciences	1	1	466

Terje R. Pedersen

126

Publications

40.1K

Citations

H-Index

Page 1

	Year	Citations
2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i> François Mach, Colin Baigent, Alberico L. Catapano, European Heart Journal	2019	8.4K
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias Alberico L. Catapano, Ian Graham, Guy De Backer, European Heart Journal	2016	3.1K
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Terje R. Pedersen Atherosclerosis Supplements Cardiovascular DiseaseHealth PolicyHyperlipidemiaDyslipidemiaPreventive Cardiology	2004	3.1K
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Kalevi Pyörälà, Terje R. Pedersen, John Kjekshus, Diabetes Care	1997	1.6K
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis Anne B. Rossebø, Terje R. Pedersen, Kurt Boman, New England Journal of Medicine	2008	1.6K
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias Alberico L. Catapano, Ian Graham, Guy De Backer, Atherosclerosis Lipid DisorderPreventive MedicineCardiovascular DiseaseMedicinePatient Safety	2016	1.6K
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE> Terje R. Pedersen JAMA	2005	1.5K
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes James A. de Lemos, Michael A. Blazing, Stephen D. Wiviott, JAMA Percutaneous Coronary InterventionThrombosisAcs EventCardiovascular DiseaseEarlier Initiation	2004	1.3K
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial Hallvard Holdaas, Bengt Fellström, Alan G. Jardine, The Lancet TransplantationCardiovascular DiseaseKidney TransplantKidney TransplantationCardiac Outcomes	2003	920
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Michelle L. O’Donoghue, Sergio Fazio, Robert P. Giugliano, Circulation	2019	895

Page 1